# Ceribell │ AI-Powered Point-of-Care EEG

> Ceribell develops portable, AI-assisted electroencephalography systems for hospital acute care. Trained bedside providers apply disposable EEG wearables, a portable recorder captures brain activity, Clarity estimates seizure burden and monitors delirium, and a cloud portal supports remote clinician review. Its U.S. hospital business combines wearable sales with monthly subscriptions.

- **Founded:** 2014
- **Headquarters:** Sunnyvale, United States
- **Founders:** Xingjuan (Jane) Chao (Co-founder, President and CEO), Josef Parvizi (Co-founder and Chief Medical Adviser), Chris Chafe (Co-founder; Stanford music researcher)
- **Products:** Ceribell Point-of-Care EEG System, Clarity seizure monitoring, Ceribell EEG Portal, Neonatal and pediatric products, Clarity delirium monitoring
- **Notable:** Initial Ceribell System FDA 510(k) clearance in 2017; first commercial sales in 2018., 2020 DECIDE prospective observational study enrolled 181 patients across five academic sites. Median rapid EEG setup was five minutes versus 239 minutes for conventional EEG., Nasdaq trading under CBLL began October 11, 2024.

## Products & services

- **Ceribell Point-of-Care EEG System** — Portable recorder, disposable electrode wearables and remote EEG portal for rapid setup and continuous acute-care brain monitoring; first commercial sales in 2018.
- **Clarity seizure monitoring** — Machine-learning analysis refreshed every ten seconds; estimates seizure burden over the previous five minutes and alerts to suspected continuous seizures. Initial algorithm clearance in 2019.
- **Ceribell EEG Portal** — Cloud-based remote review of live EEG waveforms, annotations and seizure-burden trends.
- **Neonatal and pediatric products** — Age-appropriate headbands and neonatal headcap; commercial launch initiated in 2026 following a pilot, with neonatal Clarity clearance announced in January 2026.
- **Clarity delirium monitoring** — FDA-cleared in December 2025: analysis of EEG biomarkers associated with delirium; continuous score updated every ten seconds.
- **Quantitative EEG trending and amplitude-integrated EEG** — Cleared September 30, 2026: alpha-delta ratio, relative alpha, burst suppression and aEEG. Company expects a software rollout in the first half of 2027; not described here as already deployed.

## Achievements

- Initial Ceribell System FDA 510(k) clearance in 2017; first commercial sales in 2018.
- 2020 DECIDE prospective observational study enrolled 181 patients across five academic sites. Median rapid EEG setup was five minutes versus 239 minutes for conventional EEG.
- Nasdaq trading under CBLL began October 11, 2024.
- 2025 revenue increased 36% over 2024 to USD 89.1 million.
- 712 active accounts at June 30, 2026.
- September 30, 2026 clearance for quantitative EEG trending and aEEG without age restriction.

## Latest updates

- **2026-05** — Q1 results reported commercial launch initiation for neonatal and pediatric offerings following a successful pilot.
- **2026-08** — Q2 revenue USD 28.1 million, 712 active accounts and USD 19.3 million net loss; annual revenue guidance raised to USD 114-117 million.
- **2026-08** — CMS delirium NTAP announced, effective October 1, 2026, with up to USD 2,171 for eligible Medicare inpatient cases.
- **2026-09** — FDA quantitative EEG trending and aEEG clearance; automatic software update expected in the first half of 2027.

## Links

- Website: https://ceribell.com/
- LinkedIn: https://www.linkedin.com/company/ceribell/
- Twitter/X: https://twitter.com/ceribelleeg
- YouTube: https://www.youtube.com/@ceribellEEG
- Instagram: https://instagram.com/ceribellpoceeg
- Facebook: https://www.facebook.com/61554263476690

---

Profile page: https://yespress.io/ceribell-ai-powered-point-of-care-eeg
Published by YesPress — https://yespress.io
Last updated: 2026-10-02